Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Feb;31(2):148–150. doi: 10.1128/aac.31.2.148

Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

R J Fass
PMCID: PMC174680  PMID: 3566244

Abstract

Eighty-three patients with serious urinary tract infections were treated with oral ciprofloxacin. Of these patients, 79 were hospitalized, and 41 had known structural or neurologic abnormalities of the urinary tract. The most common pathogens were members of the family Enterobacteriaceae (MICs, less than or equal to 0.06 microgram/ml), Pseudomonas aeruginosa (MICs, 0.13 to 2 micrograms/ml), and Enterococcus faecalis (MICs, 0.5 to 2 micrograms/ml). Sixty-eight patients were able to be evaluated for determining efficacy; all responded symptomatically, and all urinary pathogens were eradicated on days 3 to 5 of treatment. Five patients, who were treated for a relatively short duration (2 to 10 days), relapsed 5 to 9 days posttreatment. Six patients became colonized with yeasts during treatment, and seven patients developed bacterial reinfections 5 to 9 days posttreatment. All patients whose infections relapsed or who developed infections with new organisms had neurogenic bladders, structural abnormalities of the genitourinary tract, or urinary catheters. There was no instance of bacteria developing resistance during treatment. Ciprofloxacin probably caused nausea with or without vomiting in 7 of the 83 patients, headache in 3 patients, and mild elevation of hepatic enzymes in 2 patients; other adverse reactions were observed but were probably not drug related. Oral ciprofloxacin was effective and safe for the treatment of serious urinary tract infections caused by a variety of bacterial pathogens.

Full text

PDF
148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcieri G., August R., Becker N., Doyle C., Griffith E., Gruenwaldt G., Heyd A., O'Brien B. Clinical experience with ciprofloxacin in the USA. Eur J Clin Microbiol. 1986 Apr;5(2):220–225. doi: 10.1007/BF02013994. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Fass R. J., Anhalt J. P., Neu H. C., Thornsberry C., Tilton R. C., Painter B. G., Washington J. A., 2nd Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. J Clin Microbiol. 1985 Jun;21(6):880–883. doi: 10.1128/jcm.21.6.880-883.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N., Thornsberry C., Ayers L. W., Gerlach E. H., Sommers H. M. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother. 1984 May;25(5):633–637. doi: 10.1128/aac.25.5.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boerema J., Boll B., Muytjens H., Branolte J. Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother. 1985 Aug;16(2):211–217. doi: 10.1093/jac/16.2.211. [DOI] [PubMed] [Google Scholar]
  5. Eron L. J., Harvey L., Hixon D. L., Poretz D. M. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother. 1985 Aug;28(2):308–310. doi: 10.1128/aac.28.2.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fass R. J. The quinolones. Ann Intern Med. 1985 Mar;102(3):400–402. doi: 10.7326/0003-4819-102-3-400. [DOI] [PubMed] [Google Scholar]
  8. Finch R., Whitby M., Craddock C., Holliday A., Martin J., Pilkington R. Clinical evaluation of treatment with ciprofloxacin. Eur J Clin Microbiol. 1986 Apr;5(2):257–259. doi: 10.1007/BF02014005. [DOI] [PubMed] [Google Scholar]
  9. Giamarellou H., Galanakis N., Dendrinos C., Stefanou J., Daphnis E., Daikos G. K. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol. 1986 Apr;5(2):232–235. doi: 10.1007/BF02013996. [DOI] [PubMed] [Google Scholar]
  10. Gonzalez M. A., Uribe F., Moisen S. D., Fuster A. P., Selen A., Welling P. G., Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):741–744. doi: 10.1128/aac.26.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Guibert J., Destrée D., Konopka C., Acar J. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. Eur J Clin Microbiol. 1986 Apr;5(2):247–248. doi: 10.1007/BF02014000. [DOI] [PubMed] [Google Scholar]
  12. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lipsky B. A., Inui T. S., Plorde J. J., Berger R. E. Is the clean-catch midstream void procedure necessary for obtaining urine culture specimens from men? Am J Med. 1984 Feb;76(2):257–262. doi: 10.1016/0002-9343(84)90782-4. [DOI] [PubMed] [Google Scholar]
  14. Mehtar S., Drabu Y., Blakemore P. Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria. Eur J Clin Microbiol. 1986 Apr;5(2):248–251. doi: 10.1007/BF02014001. [DOI] [PubMed] [Google Scholar]
  15. Panichi G., Pantosti A., Testore G. P. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. J Antimicrob Chemother. 1983 Jun;11(6):589–592. doi: 10.1093/jac/11.6.589. [DOI] [PubMed] [Google Scholar]
  16. Peters H. J. Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection. Eur J Clin Microbiol. 1986 Apr;5(2):253–255. doi: 10.1007/BF02014003. [DOI] [PubMed] [Google Scholar]
  17. Platt R. Quantitative definition of bacteriuria. Am J Med. 1983 Jul 28;75(1B):44–52. doi: 10.1016/0002-9343(83)90072-4. [DOI] [PubMed] [Google Scholar]
  18. Ronald A. R., Turck M., Petersdorf R. G. A critical evaluation of nalidixic acid in urinary-tract infections. N Engl J Med. 1966 Nov 17;275(20):1081–1089. doi: 10.1056/NEJM196611172752001. [DOI] [PubMed] [Google Scholar]
  19. Saavedra S., Ramírez-Ronda C. H., Nevárez M. Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria. Eur J Clin Microbiol. 1986 Apr;5(2):255–257. doi: 10.1007/BF02014004. [DOI] [PubMed] [Google Scholar]
  20. Sanders C. C., Sanders W. E., Jr, Goering R. V., Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984 Dec;26(6):797–801. doi: 10.1128/aac.26.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Scully B. E., Neu H. C., Parry M. F., Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet. 1986 Apr 12;1(8485):819–822. doi: 10.1016/s0140-6736(86)90937-2. [DOI] [PubMed] [Google Scholar]
  22. Stamm W. E., Counts G. W., Running K. R., Fihn S., Turck M., Holmes K. K. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982 Aug 19;307(8):463–468. doi: 10.1056/NEJM198208193070802. [DOI] [PubMed] [Google Scholar]
  23. Thomas M. G., Ellis-Pegler R. B. Enoxacin treatment of urinary tract infections. J Antimicrob Chemother. 1985 Jun;15(6):759–763. doi: 10.1093/jac/15.6.759. [DOI] [PubMed] [Google Scholar]
  24. Van Poppel H., Wegge M., Dammekens H., Chysky V. Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis. Eur J Clin Microbiol. 1986 Apr;5(2):251–253. doi: 10.1007/BF02014002. [DOI] [PubMed] [Google Scholar]
  25. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES